Streetbeat News

Analyst Ratings

CADE

Morgan Stanley analyst Manan Gosalia has reiterated an Equal-Weight rating on Cadence Bank (NYSE:CADE) and maintained a $23 price target.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 3:33 pm

OZK

Morgan Stanley analyst Manan Gosalia has reiterated an Equal-Weight rating on Bank OZK and maintained a $35 price target.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 3:32 pm

BAC

Morgan Stanley analyst Betsy Graseck maintains an Equal-Weight rating on Bank of America (NYSE:BAC) and raises the price target from $32 to $33.

Portfolio Pulse from Benzinga Newsdesk

July 07, 2023 | 3:29 pm

NVDA

Tigress Financial analyst Ivan Feinseth maintains a 'Buy' rating on NVIDIA (NASDAQ:NVDA) and raises the price target from $320 to $560.

Portfolio Pulse from richadhand@benzinga.com

July 07, 2023 | 3:24 pm

KLAC

Shares of KLA Corp (NASDAQ:KLAC) were slightly higher on Friday, despite a downgrade from KeyBanc Capital Markets. Analyst Steve Barger downgraded the rating for KLA from Overweight to Sector Weight, citing that the shares may be overpriced due to a delayed cyclical upturn in the semiconductor industry. Barger believes that while a cyclical upturn is coming, it's unclear when it will happen, and until then, KLA’s stock valuation is not compelling.

Portfolio Pulse from Priya Nigam

July 07, 2023 | 3:23 pm

INM

InMed Pharmaceuticals Inc. (NASDAQ:INM) has published positive top-line data from its INM-755 Phase II study for the treatment of epidermolysis bullosa (EB), a rare genetic dermatological condition. The study supports further development of the cannabinol-based topical skin cream, INM-755. Following the data, InMed is exploring commercial partnerships for further development and distribution of the cream. The company is also open to early monetization opportunities through the sale or out-licensing of the program.

Portfolio Pulse from Javier Hasse

July 07, 2023 | 3:22 pm

EQNR

Equinor's (NYSE:EQNR) short percent of float has fallen 18.52% since its last report, with 6.89 million shares sold short, which is 0.22% of all regular shares available for trading. This decrease in short interest could signal a more bullish market sentiment towards the stock. Compared to its peers, Equinor has less short interest.

Portfolio Pulse from Benzinga Insights

July 07, 2023 | 3:16 pm

EPD

Enterprise Prods Partners's (NYSE:EPD) short percent of float has risen 16.0% since its last report, with 12.78 million shares sold short, which is 0.87% of all regular shares available for trading. This increase in short interest can signal that investors have become more bearish. However, compared to its peers, the company has less short interest as a percentage of float, which is 3.58% on average.

Portfolio Pulse from Benzinga Insights

July 07, 2023 | 3:16 pm

EOG

EOG Resources's short percent of float has fallen 7.19% since its last report, with 7.51 million shares sold short, which is 1.29% of all regular shares available for trading. This decrease in short interest could signal a more bullish market sentiment towards EOG. Compared to its peers, EOG has less short interest as a percentage of float, with an average of 6.11%.

Portfolio Pulse from Benzinga Insights

July 07, 2023 | 3:16 pm

CMPS

COMPASS Pathways (NASDAQ:CMPS) has projected a 2027 commercialization timeline for its psilocybin-assisted therapy, pending Phase 3 clinical trial success. The company is currently conducting a Phase 3 clinical program for its proprietary psilocybin formula, COMP360, for treatment-resistant depression. Additionally, COMPASS is undertaking concurrent Phase 2 clinical studies using COMP360 for PTSD and anorexia nervosa. H.C. Wainwright reiterated their 'Buy' rating on COMPASS Pathways, maintaining its $120 per share price target.

Portfolio Pulse from The Dales Report

July 07, 2023 | 3:13 pm